🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Challenge

The sexually transmitted infection are escalating around the world, with estimates suggesting more than 82 million new cases annually. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Health officials are deeply concerned about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

According to results released by a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an comparable level with the existing first-line therapy, which uses an injection and a pill. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in many developing nations.

Doctors treating patients have shared hope. The availability of a single-dose, oral treatment such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.